What is the starting dose of Flexeril (cyclobenzaprine)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: December 31, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Starting Dose of Flexeril (Cyclobenzaprine)

The recommended starting dose of cyclobenzaprine (Flexeril) is 5 mg three times daily, which can be increased to 10 mg three times daily based on individual patient response. 1

Standard Dosing Regimen

  • Start with 5 mg three times daily for most patients, as this represents the FDA-approved initial dose that balances efficacy with tolerability 1
  • The dose may be increased to 10 mg three times daily after assessing initial response and tolerability, typically within the first few days of treatment 1
  • Treatment duration should be limited to 2-3 weeks, as cyclobenzaprine is indicated only for acute musculoskeletal conditions and prolonged use is not recommended 1

Evidence Supporting Lower Starting Doses

The 5 mg three times daily starting dose is supported by robust clinical trial data showing:

  • The 5 mg dose is as effective as 10 mg three times daily for relief of muscle spasm, local pain, and improved range of motion 2
  • Lower incidence of sedation with 5 mg compared to 10 mg (the most common adverse effect), making it better tolerated while maintaining therapeutic benefit 2
  • Onset of relief occurs within 3-4 doses of the 5 mg regimen, demonstrating rapid therapeutic action 2
  • Treatment efficacy is greatest in the first 4 days, with declining benefit after the first week, supporting short-term use 3

Special Population Considerations

  • Elderly patients should receive less frequent dosing due to increased risk of adverse effects, though specific dose reductions are not defined in the FDA label 1
  • Hepatically impaired patients require less frequent dosing to avoid drug accumulation 1
  • The 2.5 mg three times daily dose was not significantly more effective than placebo in clinical trials and should not be used 2

Clinical Pearls and Pitfalls

  • Avoid the common error of starting at 10 mg three times daily in all patients, as this increases sedation risk without additional benefit for most individuals 2
  • Drowsiness is dose-related and the most common adverse effect, occurring alongside dry mouth; starting at 5 mg minimizes this while maintaining efficacy 2, 3
  • Efficacy is independent of sedation, as demonstrated by subanalysis showing meaningful treatment effects in patients who did not report somnolence 2
  • Combination with NSAIDs like ibuprofen does not provide additional benefit over cyclobenzaprine monotherapy for acute neck or back pain with muscle spasm 4

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.